Eighty percent of patients with Diabetes mellitus die a thrombotic death. Seventy-five percent of these deaths is due to cardiovascular complications, and the remainder is due to cerebrovascular events and peripheral vascular complications. Vascular endothelium, the primary defense against thrombosis, is abnormal in diabetes. Endothelial abnormalities undoubtedly play a role in the enhanced activation of platelets and clotting factors seen in diabetes. Coagulation activation markers, such as prothrombin activation fragment 1+2 and thrombin-anti-thrombin complexes, are elevated in diabetes. The plasma levels of many clotting factors including fibrinogen, factor VII, factor VIII, factor XI, factor XII, kallikrein, and von Willebrand factor are elevated in diabetes. Conversely, the level of the anticoagulant protein C (PC) is decreased. The fibrinolytic system, the primary means of removing clots, is relatively inhibited in diabetes due to abnormal clot structures that are more resistant to degradation and an increase in plasminogen activator inhibitor type 1 (PAI-1). Increased circulating platelet aggregates, increased platelet aggregation in response to platelet agonists, increased platelet contractile force (PCF), and the presence of higher plasma levels of platelet release products, such as beta-thromboglobulin, platelet factor 4, and thromboxane B(2), demonstrate platelet hyperactivity in diabetes. This constellation of findings supports the clinical observation that diabetes is a hypercoagulable state. This article briefly reviews the published evidence for this conclusion and the putative roles played by hyperglycemia and hyperinsulinemia in its development.Related ArticlesReview Type 2 diabetes: an atherothrombotic syndrome.
Curr Mol Med. 2005Review
Type 2 diabetes: an atherothrombotic syndrome.
Dunn EJ, Grant PJ. Curr Mol Med. 2005 May; 5(3):323-32. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.
Semin Nephrol. 2004
Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.
Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Semin Nephrol. 2004 Sep; 24(5):495-501. Review Von Willebrand factor in diabetic angiopathy.
Diabetes Metab. 1998Review
Von Willebrand factor in diabetic angiopathy.
Kessler L, Wiesel ML, Attali P, Mossard JM, Cazenave JP, Pinget M. Diabetes Metab. 1998 Sep; 24(4):327-36. Review Platelet function, coagulopathy, and impaired fibrinolysis in diabetes.
Cardiol Clin. 2004Review
Platelet function, coagulopathy, and impaired fibrinolysis in diabetes.
Sobel BE, Schneider DJ. Cardiol Clin. 2004 Nov; 22(4):511-26. Disturbances of haemostasis in diabetes mellitus.
Dis Markers. 2003
Disturbances of haemostasis in diabetes mellitus.
Fattah MA, Shaheen MH, Mahfouz MH. Dis Markers. 2003-2004; 19(6):251-8. Hyperglycemia increases susceptibility to ischemic necrosis.
Biomed Res Int. 2013
Hyperglycemia increases susceptibility to ischemic necrosis.
Lévigne D, Tobalem M, Modarressi A, Pittet-Cuénod B. Biomed Res Int. 2013; 2013:490964. Epub 2012 Dec 23.Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Cardiovasc Diabetol. 2012
Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Hernestål-Boman J, Norberg M, Jansson JH, Eliasson M, Eriksson JW, Lindahl B, Johansson L. Cardiovasc Diabetol. 2012 Dec 18; 11:152. Epub 2012 Dec 18.Management and Treatment Guidelines for Sepsis in Pediatric Patients.
Open Inflamm J. 2011
Management and Treatment Guidelines for Sepsis in Pediatric Patients.
El-Wiher N, Cornell TT, Kissoon N, Shanley TP. Open Inflamm J. 2011 Oct 7; 4(Suppl 1-M11):101-109.